Low rate of neutralising antibody formation to botulinum toxin type A in the course of treatment of primary axillary hyperhidrosis

Background: Hyperhidrosis is excessive sweating beyond that required to return body temperature to normal. Treatment of hyperhidrosis with botulinum toxin type A (BoNTA: BOTOX®, Allergan, Inc.) injections has been shown to be effective and well-tolerated. The development of neutralizing antibodies that interfere with clinical effectiveness is a risk of repeated exposure to BoNTA. Several factors can influence the development of neutralizing antibodies to BoNTA. These factors include dose, intervals between treatment, and the formulation of the toxin. Objective: To assess the rate of neutralizing antibody formati…